Double short-time exposure to pirarubicin produces higher cytotoxicity against T24 bladder cancer cells

[1]  J. Witjes,et al.  The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. , 2008, European urology.

[2]  D. Lamm,et al.  Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. , 2002, The Journal of urology.

[3]  Laurence Collette,et al.  Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. , 2002, European urology.

[4]  M. Soloway,et al.  Contemporary management of stage T1 transitional cell carcinoma of the bladder. , 2002, The Journal of urology.

[5]  Gerhard Jakse,et al.  Guidelines on bladder cancer. , 2002, European urology.

[6]  S. Nilsson,et al.  A systematic overview of chemotherapy effects in urothelial bladder cancer. , 2001, Acta oncologica.

[7]  H. Kumon,et al.  The absorption of pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer , 2000, BJU international.

[8]  R. Hautmann,et al.  Tributyrin induces differentiation, growth arrest and apoptosis in androgen‐sensitive and androgen‐resistant human prostate cancer cell lines , 2000, International journal of cancer.

[9]  史郎 樋之津.  Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection : a combined analysis of trials by the Japanese urological cancer research group using smoothed hazard function , 2000 .

[10]  M. Park,et al.  Prophylactic Treatment of Superficial Bladder Tumor , 1998, International journal of urology : official journal of the Japanese Urological Association.

[11]  T. Miki,et al.  [A randomized study on intravesical pirarubicin (THP) chemoprophylaxis of recurrence after transurethral resection of superficial bladder cancer]. , 1997, Hinyokika kiyo. Acta urologica Japonica.

[12]  T. Hatakeyama,et al.  [Investigation of retention time of intravesical instillation therapy with pirarubicin (THP)]. , 1996, Gan to kagaku ryoho. Cancer & chemotherapy.

[13]  D. Lamm,et al.  Bladder cancer, 1996 , 1996, Ca.

[14]  T. Fukushima,et al.  [Pharmacokinetics and action mechanism of anthracyclines]. , 1992, Gan to kagaku ryoho. Cancer & chemotherapy.

[15]  Y. Matsumura.  Cooperative Study of Therapy of Superficial Bladder Cancer by Intravesical Instillation of Pirarubicin , 1990, American Journal of Clinical Oncology.

[16]  H. Akaza,et al.  Comparative investigation on use of (2''R)-4'-O-tetrahydropyranyl-adriamycin and adriamycin as intravesical chemotherapy for superficial bladder tumors. , 1988, Urology.

[17]  D. Pode,et al.  The mechanism of human bladder tumor implantation in an in vitro model. , 1986, The Journal of urology.

[18]  A B West,et al.  Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. , 1986, The Journal of urology.

[19]  S. Takamoto,et al.  [Flow cytometric analysis of the effect of THP-adriamycin on the cell cycle traverse of RPMI-8402 cells--comparison with adriamycin]. , 1986, Gan to kagaku ryoho. Cancer & chemotherapy.

[20]  K. Kimura,et al.  Mechanism of inhibition of DNA polymerases by 4'-epiadriamycin and 4'-O-tetrahydropyranyladriamycin. , 1983, Gan.

[21]  S. Loening,et al.  Superficial bladder cancer: progression and recurrence. , 1983, The Journal of urology.

[22]  W Lutzeyer,et al.  Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. , 1982, The Journal of urology.

[23]  M. Soloway,et al.  Urothelial susceptibility to tumor cell implantation influence of cauterization , 1980, Cancer.